254 related articles for article (PubMed ID: 24290735)
1. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
Borker R
J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
[TBL] [Abstract][Full Text] [Related]
4. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
6. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
7. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
8. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
9. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
[TBL] [Abstract][Full Text] [Related]
10. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
12. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Choueiri TK; Duh MS; Clement J; Brick AJ; Rogers MJ; Kwabi C; Shah K; Percy AG; Antràs L; Jayawant SS; Chen K; Wang ST; Luka A; Neary MP; McDermott D; Oh WK
BJU Int; 2010 May; 105(9):1247-54. PubMed ID: 19863525
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Geynisman DM; Hu JC; Liu L; Tina Shih YC
Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
18. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
[TBL] [Abstract][Full Text] [Related]
19. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
20. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]